US › Healthcare

Annovis Bio Inc (ANVS)

US · Healthcare · Biotechnology

$1.87+8.72%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-17.6M

Profit YoY

-218.0%

EPS

$-0.63

EPS estimate

$-0.35

EPS came in at -0.63 against a street estimate of -0.35 — a miss of 80.0%.

Key statistics

Market cap

$73.2M

Forward P/E

0.0

P/B

23.82

Book value

$0.11

EPS (TTM)

$-1.71

52-week high

$5.50

52-week low

$1.54

50-day MA

$1.83

200-day MA

$2.50

Beta

1.24

Analyst view

Analysts rate Annovis Bio Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $11.00.

Shareholding

Insiders

8.25%

Institutions

16.46%

Largest institutional holders

Fund	Stake
Marshall Wace Asset Management Ltd	2.79%
Vanguard Group Inc	2.17%
Vanguard Capital Management, LLC	2.05%
Two Sigma Investments LLC	1.48%
Renaissance Technologies Corp	0.82%
Geode Capital Management, LLC	0.58%
Susquehanna International Group, LLP	0.51%
Northern Trust Corp	0.33%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Annovis Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.